diagnost tool
deliv strongest volum growth year
beat rais safe buy pt
deliv strongest volum growth rate y/i sinc
take share labcorp lh hold result gain
live larg health plan expect share gain continu
like meanwhil encourag compani beat though
magnitud rais high enough move stock higher today
think matter guid conserv help repair credibl last year
miss matter setup look good view
rel safe reiter buy rate rais pt
dividend yield believ fit nice mid/larg cap incom portfolio
beat adj ep beat rev
y/i beat volum
beat driven organ volum
expand network access share gain expect
increas throughout beyond ad point volum growth
step certain deal anniversari revenue /req better our/
street includ pama hit unit price
saw benefit y/i patient concess payor test mix
rais guid rais ep guid look conserv us beat
street estim top-lin bottom-lin rais
revenue guid y/i increas
midpoint rais adj ep guid y/i greater
howev high end guid match consensu
model rais rev y/i y/i
rais revenu estim y/i
reiter revenu estim rais adj ep
penni maintain adj ep
estim assum chang expect pama cut
growth new acquisit like conserv
share gain expect continu quest gain health plan access
live anthem horizon georgia indic expect market share
gain continu quest reiter view expand
health plan coverag mark increment billion revenu opportun quest also
continu grow tune points/year howev compani
indic potenti deal get bigger complex take longer
close quest continu target cost save invigor
new lab act revers pama pain investor prudenc warrant
assum chang statu quo pama pain cautious optimist
potenti new lab act bill introduc hous year could
possibl delay next round data report one year expand
scope applic lab includ hospit lab would result better
reimburs lh bill mark progress made acla view
odd pama fix low view lab act free call option pama fix
price close busi octob
largest clinic lab us
focus routin gene-bas esoter test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
reiter buy rate rais pt use
multipl adj ep estim y/i formerli pt
use multipl adj ep estim
share gain expect continu quest gain health plan access
live anthem horizon georgia indic expect market
share gain continu quest reiter view expand health plan
coverag increment billion revenu opportun
becom one prefer lab unit recal unitedhealthcar
select ameripath/dermpath subsidiari labcorp
lh biorefer lab genedx invita mayo clinic lab
join newli creat prefer lab network pln effect juli pln
seek steer member get lowest cost test best qualiti ie reduc
wait time servic on-line schedul lab measur quarterli
perform indic unclear impact part pln
might indic price remain work
in-network lab think sinc oper prefer lab
network think addit volum come name better care
servic lower price
acquisit front quest remain activ involv sever health system
evalu hospit outreach strategi indic expect add
point revenu growth howev indic potenti deal get
larger becom complex thu take longer close seem
grow awar low base financi impact pama
hospit outreach lab expect ramp consolid lab
beyond ad point growth vs growth
sum acquisit cost
lab act hope alter cours pama note quit
variabl outstand rate come next pama period would
take effect believ lh stock continu price
statu quo on-going pama cut encourag introduct
lab act hous delay next round pama data report one year
lab act look provid applic laboratori addit time report
privat payer data requir neutral third parti recommend congress
improv pama data collect rate set process expect
process least run take time play believ
acla compel case go hh us govern thu
think probabl materi chang pama low
on-going push retail quest expect expand footprint expand access
directli consum end locat safeway wal-
mart store quest expand footprint store beyond state
tx fl oper wal-mart store see path go
forward quest lab send-out work first ever clinic
locat georgia open last month quest also indic dialogu
retail beyond safeway continu work cvs/aetna
minuteclin
quest direct aim make easier patient get test want similar
initi awar rate well privately-held
binx health quest live quest direct provid individu
abil log onto quest order one test without consult
physician individu schedul time come patient servic
center psc simpli come without appoint provid sampl
test manag indic offer alreadi well receiv
particularli among millenni though clarifi age quest call demand
std test includ ct/ng syphili total std panel
expand std panel includ std test hcv hbv test
gluten intoler panel
chang long-term target look drive revenu growth compound-annual-growth-rate
earn growth exclud benefit share
buy unchang target price octob
diagnost tool
buyback remind quest novemb lower four-year earn
growth target compound-annual-growth-rate mid-to-high-singl digit cite headwind
reimburs pama carryov test
headwind hcvg vit wage inflat
possibl expans quest manag remain activ involv larg
hospit oper quest help lower lab spend
colorado believ expans quest work across unit state
would mark materi posit catalyst price stock
view
in-network statu extend commerci cover live
us indic expect organ volum growth build year primarili
new live target opportun time build
revenu pharma custom newer clinic trial connect program
expect lower cost structur offset expect
reimburs impact see opportun reduc test denial
opportun acceler digit opportun consolid
six immuno-assay provid one opportun year quest
narrow immuno-assay provid plan announc singular
winner soon expect end
buy unchang target price octob
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price octob
diagnost tool
canaccord genuiti estim compani report
buy unchang target price octob
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research iii best author analyst
knowledg she/h receipt materi non-publ inform issuer
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin octob et
date time product octob et
pt use multipl adj ep estim y/i
laboratori corpor america hold lh
pt use multipl adj ep estim
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
buy unchang target price octob
diagnost tool
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
